OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1754-1764
Closed Access | Times Cited: 16
Jianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1754-1764
Closed Access | Times Cited: 16
Showing 16 citing articles:
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Shiwen Yang, Ying Liu, Shengzhao Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Shiwen Yang, Ying Liu, Shengzhao Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects
Xuejun He, Gege Liu, Xinyan Chen, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 7, pp. 655-661
Closed Access | Times Cited: 13
Xuejun He, Gege Liu, Xinyan Chen, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 7, pp. 655-661
Closed Access | Times Cited: 13
Modulation of dipeptidyl peptidase IV by Rooibos tea metabolites towards type 2 diabetes care: Evidence from molecular dynamics simulation and density functional theory
Lukman HY, Aribisala JO, Ayesha Akoonjee, et al.
Scientific African (2024) Vol. 24, pp. e02173-e02173
Open Access | Times Cited: 4
Lukman HY, Aribisala JO, Ayesha Akoonjee, et al.
Scientific African (2024) Vol. 24, pp. e02173-e02173
Open Access | Times Cited: 4
Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis
Lei Xu, Yike Wu, Jiyifan Li, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e088687-e088687
Open Access
Lei Xu, Yike Wu, Jiyifan Li, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e088687-e088687
Open Access
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Xiayun Ni, Lei Zhang, Xiaojun Feng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Xiayun Ni, Lei Zhang, Xiaojun Feng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers
Yunzhe Huang, Ran Liu, Yaqin Wang, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 7, pp. 945-956
Closed Access | Times Cited: 11
Yunzhe Huang, Ran Liu, Yaqin Wang, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 7, pp. 945-956
Closed Access | Times Cited: 11
Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
Yu Zhang, Panpan Xie, Yamei Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Yu Zhang, Panpan Xie, Yamei Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus
Haigang Cui, Xin Luo, Mingwei Chen, et al.
Current Drug Targets (2023) Vol. 24, Iss. 8, pp. 648-661
Closed Access | Times Cited: 4
Haigang Cui, Xin Luo, Mingwei Chen, et al.
Current Drug Targets (2023) Vol. 24, Iss. 8, pp. 648-661
Closed Access | Times Cited: 4
Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes
Shujun Zhang, Fen Wang, Lei Xie, et al.
Journal of Diabetes Investigation (2024)
Open Access | Times Cited: 1
Shujun Zhang, Fen Wang, Lei Xie, et al.
Journal of Diabetes Investigation (2024)
Open Access | Times Cited: 1
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Leili Gao, Zhifeng Cheng, Benli Su, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 785-795
Closed Access | Times Cited: 7
Leili Gao, Zhifeng Cheng, Benli Su, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 785-795
Closed Access | Times Cited: 7
Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
Yao Wang, Chengxia Jiang, Xiaolin Dong, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2774-2786
Closed Access
Yao Wang, Chengxia Jiang, Xiaolin Dong, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2774-2786
Closed Access
Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
Yunjie Teng, Fan Xue, Rui Yu, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access
Yunjie Teng, Fan Xue, Rui Yu, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access
Analysis of the Structural Transformations Underlying the Design of Innovative Next-in-Class Drugs
Konstantin V. Balakin
Russian Journal of General Chemistry (2023) Vol. 93, Iss. S2, pp. S401-S425
Closed Access | Times Cited: 1
Konstantin V. Balakin
Russian Journal of General Chemistry (2023) Vol. 93, Iss. S2, pp. S401-S425
Closed Access | Times Cited: 1
Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds
Shubham Batra, Prabhjeet Kaur Bamrah, Manjusha Choudhary
Egyptian Journal of Basic and Applied Sciences (2022) Vol. 10, Iss. 1, pp. 69-82
Open Access | Times Cited: 2
Shubham Batra, Prabhjeet Kaur Bamrah, Manjusha Choudhary
Egyptian Journal of Basic and Applied Sciences (2022) Vol. 10, Iss. 1, pp. 69-82
Open Access | Times Cited: 2
Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers
Yueyue Liu, Xiaoyuan Huyan, Qian Zhang, et al.
Clinical Pharmacology in Drug Development (2022) Vol. 12, Iss. 4, pp. 376-384
Closed Access | Times Cited: 1
Yueyue Liu, Xiaoyuan Huyan, Qian Zhang, et al.
Clinical Pharmacology in Drug Development (2022) Vol. 12, Iss. 4, pp. 376-384
Closed Access | Times Cited: 1
